Mohamed Aboulghar, M.D., Walid Saber, M.D., Yahia Amin, M.D., Mona Aboulghar, M.D., Gamal Serour, F.R.C.O.G., Ragaa Mansour, M.D., Ph.D.
Volume 101, Issue 1, Pages 134-137, January 2014
To assess the value of routine antimüllerian hormone (AMH) assays in patients considered high risk for cancellation.
Prospective controlled study.
A private IVF center, Cairo, Egypt.
In total 4,917 patients received counseling before starting IVF/intracytoplasmic sperm injection (ICSI). They were comprised of group A1 (n = 1,335), who were considered to be at risk for cancellation after ovarian stimulation, and group A2 (n = 3,582), who were considered low risk for cancellation. A control group, B (n = 4,639), included group B1 (n = 1,248) and group B2 (n = 3,391) based on the same criteria as groups A1 and A2.
An AMH assessment was performed for group A1. All of the patients were stimulated using the long GnRH agonist protocol. Patients with low AMH levels received the flare-up protocol.
Main Outcome Measure(s):
The cancellation of IVF/ICSI cycles before or after stimulation, as well as the pregnancy rates (PR) in relation to AMH levels.
The group A1 patients (6.4%) did not start IVF due to low AMH, and some (6.6%) had their cycles canceled due to poor responses, compared with 2.6% in group A2 and 13.2% in group B1. The clinical PR was 42% in patients with normal AMH and 20% in patients with low AMH. The differences among these three groups were highly significant.
The AMH assays reduced the cancellations, cost, and stress experienced by couples.
Read the full text at: http://www.fertstert.org/article/S0015-0282(13)03100-2/fulltext